Introduction
============

Although *Enterobacteriaceae* are normal flora of the human intestinal system, they are also common pathogens causing human infections in the setting of both community-acquired and healthcare-associated infections ([@B11]; [@B33]; [@B20]; [@B15]). In this era of widespread antibiotic resistance, *Enterobacteriaceae* are no exception. Recently, the emergence of carbapenem-resistant *Enterobacteriaceae* (CRE) has become a more critical issue due to the limited therapeutic options available for these pathogens and the significant morbidity and mortality associated with CRE infections ([@B29]; [@B24]). Therefore, there is an urgent need for new treatments for these critical CRE-associated conditions.

*Lactobacillus* is one of a number of probiotics considered to be biological therapeutics and host immune-modulating biologicals that are generally recognized as safe (GRAS). Recent studies demonstrated several antimicrobial mechanisms of *Lactobacillus* such as nutrient competition, production of inhibitory compounds, immune-stimulation and competition for binding sites. In addition, *Lactobacillus* can produce lactic acid, acetic acid, formic acid and other acids to reduce intestinal pH, which may be the most important mechanism. These bacteria can also secrete certain antimicrobial molecules, such as ethanol, fatty acid, hydrogen peroxide and bacteriocins to exert the antimicrobial activity ([@B9]; [@B12]). Through these mechanisms, *Lactobacillus* has demonstrated its ability to inhibit several bacterial pathogens, including *Clostridium difficile* ([@B21]), *Escherichia coli* ([@B18]), *Shigella* spp. ([@B22]), *Streptococcus mutans* ([@B1]), *Pseudomonas aeruginosa* ([@B14]), and *Staphylococcus aureus* ([@B16]). However, no previous studies have assessed the antimicrobial activity of *Lactobacillus* against CRE. Thus, we conducted this study to identify suitable lactobacilli that have anti-CRE activity with *in vitro* tolerance to pepsin and bile salts.

Materials and Methods {#s1}
=====================

Bacterial Strains and Culture Conditions
----------------------------------------

Fifty-seven *Lactobacillus* spp. strains encompassing nine species were obtained from Department of Food Science at the National Chiayi University in Chiayi, Taiwan. Species confirmation was performed by 16S rDNA sequencing. A fragment of the 16S rDNA was amplified by PCR. After amplification, the amplicons were separated by gel electrophoresis and sequenced. Sequences were compared with the NCBI GenBank database using the BLAST search tool to find the closest matches. The basic growth media for LAB were Man-Rogosa-Sharpe (MRS; Oxoid Inc., Ogdensburg, NY, United States).

Twenty clinical strains, including 10 different pulse field gel electrophoresis (PFGE) genotyped carbapenem-resistant *Escherichia coli* (CREC) and *Klebsiella pneumoniae* (CRKP) strains were isolated from Chi Mei Medical Center ([@B19]; [@B30]). Species confirmations were performed using the VITEK 2 automated system (bioMérieux, Marcy l'Etoile, France) with standard biochemical methods. Mueller Hinton (MH) broth (Difco Laboratories, Detroit, MI, United States) were used for bacterial pathogens. The isolates were stored at −80°C in Protect Bacterial Preservers (Technical Service Consultants Limited, Heywood, United Kingdom) before use.

Carbapenem susceptibility testing was performed using the disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B6]). In brief, a 0.5 McFarland turbidity standard inoculum from overnight cultures was followed by incubation of Mueller-Hinton agar plates at 35°C. The antibiotic disks were placed on the agar surface. After 16--18 h of incubation at 35°C, results were interpreted as either sensitive, intermediate, or resistant according to the inhibitory zone diameters around the disks using CLSI breakpoints. Carbapenem resistance was defined as resistance to imipenem, meropenem, doripenem, or ertapenem.

Pulsed-Field Gel Electrophoresis
--------------------------------

Pulsed-field gel electrophoresis (PFGE) for the *Escherichia coli* and *K. pneumoniae* isolates were performed as described previously ([@B19]) with a CHEF DR II apparatus (Bio-Rad Laboratories, Hercules, CA, United States). Briefly, bacterial chromosomal DNAs were digested using XbaI (New England Biolabs, Beverly, MA, United States). Electrophoresis was carried out for 22 h at 14 μC, with pulse times ranging from 2 to 40 s at 6 V/cm, using a Bio-Rad CHEF MAPPER apparatus (Bio-Rad Laboratories, Richmond, CA, United States). A dendrogram based on the unweighted pair group was generated using methods previously described. The PFGE patterns were visually examined and interpreted according to the criteria of [@B32]. The similarities of the PFGE profiles of each strain were compared using a Dice coefficient at 1.0% of tolerance and 1.0% of optimization. Isolates that had \< 80% similarity on the PFGE profiles were considered different types ([Figure 1](#F1){ref-type="fig"}).

![**(A)** PFGE of 10 isolates of carbapenem-resistant *E. coli.* **(B)** PFGE of 10 isolates of carbapenem-resistant *K. pneumoniae.*](fmicb-10-00789-g001){#F1}

Antimicrobial Susceptibility Test
---------------------------------

The procedure for broth microdilution was adapted from the CLSI protocol for antimicrobial susceptibility testing ([@B5]). Antibiotic solutions were prepared in LAB susceptibility media (90% LSM and 10% MRS broth, adjusted to pH 6.7) ([@B17]). The following antibiotics were tested: ampicillin, chloramphenicol, clindamycin, erythromycin, fusidic acid, gentamycin, kanamycin, linezolid, streptomycin, teicoplanin, trimethoprim/sulfamethoxazole (1/19), and vancomycin (Sigma-Aldrich, St. Louis, MO, United States). The antibiotic susceptibility tests and their interpretations were carried out according to the CLSI guidelines ([@B4]; [@B7]).

Pepsin Tolerance
----------------

A pepsin solution was prepared by suspending 3 mg/ml pepsin (Sigma-Aldrich, St. Louis, MO, United States) in a 0.85% sterile saline solution adjusted to pH 2.5. To test bacterial viability in the presence of pepsin, the 3 mg/ml pepsin solution, or saline at a pH of 7.0 as control, was inoculated with 10^6^ CFU/ml of *Lactobacillus* spp. and then incubated at 37°C for 4 h. The viable cell population was determined using the spread plate method. Each experiment was conducted in triplicate ([@B34]).

Bile Salt Tolerance
-------------------

The bile salt tolerance assay was performed as previously described ([@B13]). In brief, each strain was adjusted to 1 × 106 CFU/ml in 0.3% Oxgall (Sigma-Aldrich, St. Louis, MO, United States) in PBS pH 7.3, or in PBS pH 7.3 alone as a control. Survival was tested at 37°C after 24 h by the spread plate method. Each experiment was conducted in triplicate.

Cell-Free Supernatant (CFS) Preparation
---------------------------------------

Lactobacilli cell-free supernatants were cultured in MRS broth at 37°C for 24 h. The cultures were then centrifuged at 4000 rpm at 4°C for 30 min. The supernatants were sterilized by filtration through a 0.22 μm filter (Millipore, Billerica, MA, United States).

Well Diffusion Assay
--------------------

The agar well diffusion method ([@B28]) was modified to detect antimicrobial activities of supernatants isolated from *Lactobacillus* strains. First, MH agar plates were swabbed on the surface with CRE bacterial cultures. Then, 6 mm diameter wells were prepared and cell-free supernatants from isolated lactobacilli were loaded in the wells (100 μl/well). Following a 24-h incubation at 37°C, inhibition zones were recorded.

Broth Microdilution Assay
-------------------------

Broth microdilution assay was carried out as previously described ([@B3]) with some modifications. Overnight cultures of pathogenic bacteria were inoculated into fresh MHB media and seeded into 96-well plates (BD Discovery Labware, Bedford, MA, United States). The CFS of each *Lactobacillus* culture was separated into three aliquots: The first aliquot received no treatment, the second aliquot was heated at 80°C for 10 min, and the third aliquot was neutralized to pH 7.0 with 1N NaOH. A 200 μl volume of test solution, consisting of 100 μl of the pathogenic bacterial culture (final inoculum was approximately 10^6^ CFU/ml) and 100 μl of one of the CFS aliquots, was mixed into the wells. The CFSs were diluted with MRS broth and used at different percentages (i.e., 10, 20, 30, 40, 50%) in the final 200 μl volume. The minimum inhibitory percentage (MIP), defined as the lowest percentage of supernatant that can inhibit the growth of pathogen, was monitored by measuring optical density (OD600 nm). The minimum bactericidal percentage (MBP) was defined as the lowest percentage of CFS that can kill all the pathogenic bacteria, as detected by subculturing treated samples onto MH agar. All tests were done in triplication.

Time-Kill Test in Co-cultures
-----------------------------

Carbapenem-resistant *Enterobacteriaceae* and *Lactobacillus* strains were individually cultured in their respective broth medium at 37°C for 24 h. The cultures were centrifuged at 6000 rpm, 22°C for 10 min to collect the cell pellet. Then, pathogenic bacteria were inoculated at 1 × 10^6^ CFU/ml and lactobacilli at 1 × 10^5^, 1 × 10^6^, 1 × 10^7^, or 1 × 10^8^ CFU/ml into mono-cultures or 1 × 10^6^ CFU/ml pathogenic bacteria co-culture with 1 × 10^5^, 1 × 10^6^, 1 × 10^7^, or 1 × 10^8^ CFU/ml lactobacilli in tubes containing 10 ml of MRS-MH broth (1:1) ([@B8]). Mono-cultures and co-cultures were incubated at 37°C for 48 h. Samples were collected at 0, 2, 4, 8, 24, and 48 h for the determination of viable cell count and pH measurements. A 1 ml aliquot of each sample was used to prepare serial dilutions that were poured onto the appropriate agar plates; MRS agar was used for *Lactobacillus* spp., while MacConkey Agar was used for *Enterobacteriaceae*. Plates were incubated at 37°C for 24 h and colonies were counted. The assay detection limit was 100 CFU/ml ([@B27]). All tests were done in triplication.

Statistical Analysis
--------------------

The paired *t*-test was used for statistical analysis. The level of significance for all analysis was *p* \< 0.05.

Results
=======

Microbiological Characteristics of *Lactobacillus* Isolates
-----------------------------------------------------------

A total of 57 *Lactobacillu*s isolates, including *L. plantarum* (*n* = 17), *L. paracasei* (*n* = 16), *L. rhamnosus* (*n* = 8), *L. fermentum* (*n* = 6), *L. casei* (*n* = 4), *L. brevis* (*n* = 2), *L. futsaii* (*n* = 2), *L. furfuricola* (*n* = 1), and *L. sakei* (*n* = 1) were collected for this study ([Table 1](#T1){ref-type="table"}). Based on the findings from MIC testing of these *Lactobacillu*s isolates, we determined that these isolates were highly susceptible to chloramphenicol, clindamycin, erythromycin, linezolid and streptomycin with susceptibility rates ranging from 91.2 to 100%. The resistance rates of these isolates against fusidic acid, kanamycin, trimethoprim/sulfamethoxazole, teicoplanin, and vancomycin ranged from 89.5 to 100% ([Table 2](#T2){ref-type="table"}).

###### 

Name and number of each species among the 57 total *Lactobacillu*s isolates.

  --------------------------------------- -------------------------------------------------------
  *Lactobacillus brevis* (*N* = 2)        LYC1152, LYC1113
  *Lactobacillus casei* (*N* = 4)         LUC0095, LUC0123, LUC0197, LYC1229,
  *Lactobacillus fermentum* (*N* = 6)     LUC0113, LUC0168, LUC0174, LUC0182, LUC0191, LYC1120
  *Lactobacillus furfuricola* (*N* = 1)   LYC1039
  *Lactobacillus futsaii* (*N* = 2)       LYC1037, LYC1038
  *Lactobacillus paracasei* (*N* = 16)    LUC0018, LUC0040, LUC0044, LUC0048, LUC0097, LUC0180,
                                          LYC1119, LYC1142, LYC1149, LYC1151, LYC1154, LYC1156,
                                          LYC1162, LYC1164, LYC1235, LYC1237
  *Lactobacillus plantarum* (*N* = 17)    LUC0125, LUC0128, LUC0219, LYC0289, LYC1031, LYC1088,
                                          LYC1112, LYC1115, LYC1117, LYC1138, LYC1141, LYC1143,
                                          LYC1144, LYC1146, LYC1159, LYC1303, LYC1322
  *Lactobacillus rhamnosus* (*N* = 8)     LUC0103, LUC0103, LUC0115, LUC0127, LUC0192, LYC0413,
                                          LYC1065, LYC1118
  *Lactobacillus sakei* (*N* = 1)         LYC1287
  --------------------------------------- -------------------------------------------------------

###### 

Distribution of different antimicrobial agent MICs (mg/l) for 57 *Lactobacillus* isolates.

        ≤0.06   0.12   0.25   0.5   1   2    4    8    16   32   64   128   \>128
  ----- ------- ------ ------ ----- --- ---- ---- ---- ---- ---- ---- ----- -------
  AMP   2       1             3     6   33   11   1                         
  CHL                               1   5    46   5                         
  CLI   20      19     8      7     1   2                                   
  ERY   33      22                      1              1                    
  FA                                2   2    1    1    7    13   2    15    14
  GM                          1     2   9    25   15   3    1    1          
  KAN                                                            14   26    17
  LNZ                               1   4    47   5                         
  STR                                   1    1    6    29   13   7          
  TEC                                             1    1    3    2    5     45
  SXT                               2   4    1         1         1    10    38
  VAN                                                                 1     56

\(1\) SXT, only the MIC of trimethoprim is shown. (2) AMP: ampicillin; CHL, chloramphenicol; CLI, clindamycin; ERY, erythromycin; FA, fusidic acid; GM, gentamicin; KAN, kanamycin; LNZ, linezolid; STR, streptomycin; TEC, teicoplanin; SXT, trimethoprim/sulfamethoxazole (1/19); VAN, vancomycin.

*In vitro* Viability of *Lactobacillus* Isolates
------------------------------------------------

[Table 3](#T3){ref-type="table"} displays the results of the pepsin tolerance tests. The viability of 32 of the isolates was reduced by \<2 log. Another 19 isolates were totally inhibited in these simulated conditions. [Table 4](#T4){ref-type="table"} shows the results of the bile salt tolerance tests. With the exception of LYC1164, which had a 2.1-log reduction in growth, all of the isolates had a less than a 2-log reduction in cell viability after incubation in this simulated intestinal condition for 24 h. Based on the findings of these *in vitro* viability tests, we chose 31 *Lactobacillus* isolates with less than 2-log reductions in viability in both pepsin and bile salt tolerance tests. Because of their ability to survive in these simulated gastric and intestinal environments, we selected these strains for the assessment their antibacterial activity.

###### 

Pepsin tolerance test results for 57 *Lactobacillus* isolates at pH 2.5 with 3.5 mg/ml pepsin.

  *Lactobacillus* strain   Cell viability (log CFU/ml)   Reduction in cell viability (log)   
  ------------------------ ----------------------------- ----------------------------------- ------
  LUC0018                  7.04 ± 0.08                   4.54 ± 0.09                         2.50
  LUC0040                  7.14 ± 0.07                   7.01 ± 0.08                         0.13
  LUC0044                  6.81 ± 0.00                   4.59 ± 0.16                         2.22
  LUC0048                  6.93 ± 0.04                   4.50 ± 0.28                         2.43
  LUC0095                  6.89 ± 0.02                   0.00 ± 0.00                         6.89
  LUC0097                  7.08 ± 0.03                   4.60 ± 0.08                         2.48
  LUC0103                  6.54 ± 0.00                   0.00 ± 0.00                         6.54
  LUC0113                  6.15 ± 0.00                   0.00 ± 0.00                         6.15
  LUC0114                  7.11 ± 0.00                   0.00 ± 0.00                         7.11
  LUC0115                  6.90 ± 0.08                   0.00 ± 0.00                         6.90
  LUC0123                  6.50 ± 0.14                   0.00 ± 0.00                         6.50
  LUC0125                  6.83 ± 0.18                   0.00 ± 0.00                         6.83
  LUC0127                  6.69 ± 0.21                   5.89 ± 0.06                         0.80
  LUC0128                  6.89 ± 0.06                   0.00 ± 0.00                         6.89
  LUC0168                  6.83 ± 0.25                   6.68 ± 0.19                         0.15
  LUC0174                  6.92 ± 0.15                   6.81 ± 0.16                         0.11
  LUC0180                  7.05 ± 0.10                   6.60 ± 0.08                         0.45
  LUC0182                  7.08 ± 0.08                   6.90 ± 0.04                         0.18
  LUC0191                  6.86 ± 0.06                   6.36 ± 0.26                         0.50
  LUC0192                  6.63 ± 0.04                   0.00 ± 0.00                         6.63
  LUC0197                  6.80 ± 0.02                   0.00 ± 0.00                         6.80
  LUC0219                  6.48 ± 0.25                   6.23 ± 0.05                         0.25
  LYC0289                  6.39 ± 0.12                   4.85 ± 0.00                         1.54
  LYC0413                  6.48 ± 0.00                   6.11 ± 0.02                         0.37
  LYC1031                  6.72 ± 0.03                   5.09 ± 0.12                         1.63
  LYC1037                  6.50 ± 0.14                   0.00 ± 0.00                         6.50
  LYC1038                  6.44 ± 0.06                   0.00 ± 0.00                         6.44
  LYC1039                  6.63 ± 0.04                   0.00 ± 0.00                         6.63
  LYC1065                  7.10 ± 0.05                   6.89 ± 0.06                         0.21
  LYC1088                  6.65 ± 0.00                   6.50 ± 0.14                         0.15
  LYC1112                  6.81 ± 0.10                   6.59 ± 0.16                         0.22
  LYC1113                  7.24 ± 0.01                   4.93 ± 0.04                         2.31
  LYC1115                  6.85 ± 0.21                   6.54 ± 0.09                         0.31
  LYC1117                  6.57 ± 0.12                   6.24 ± 0.09                         0.33
  LYC1118                  6.93 ± 0.04                   6.77 ± 0.10                         0.16
  LYC1119                  6.83 ± 0.02                   6.54 ± 0.09                         0.29
  LYC1120                  7.11 ± 0.02                   6.68 ± 0.03                         0.43
  LYC1138                  7.04 ± 0.03                   6.95 ± 0.00                         0.09
  LYC1141                  6.99 ± 0.05                   6.70 ± 0.00                         0.29
  LYC1142                  6.85 ± 0.11                   6.81 ± 0.10                         0.04
  LYC1143                  7.09 ± 0.06                   6.94 ± 0.05                         0.15
  LYC1144                  6.98 ± 0.06                   0.00 ± 0.00                         6.98
  LYC1146                  7.00 ± 0.03                   6.03 ± 0.11                         0.97
  LYC1149                  6.90 ± 0.12                   6.44 ± 0.06                         0.46
  LYC1151                  6.78 ± 0.05                   6.20 ± 0.03                         0.58
  LYC1152                  7.03 ± 0.04                   5.15 ± 0.00                         1.88
  LYC1154                  7.19 ± 0.04                   6.89 ± 0.06                         0.30
  LYC1156                  6.90 ± 0.08                   3.60 ± 0.08                         3.30
  LYC1159                  6.96 ± 0.08                   6.88 ± 0.10                         0.08
  LYC1162                  7.22 ± 0.02                   0.00 ± 0.00                         7.22
  LYC1164                  7.18 ± 0.04                   6.81 ± 0.05                         0.37
  LYC1229                  7.02 ± 0.06                   6.96 ± 0.05                         0.06
  LYC1235                  6.95 ± 0.10                   0.00 ± 0.00                         6.95
  LYC1237                  6.97 ± 0.02                   0.00 ± 0.00                         6.97
  LYC1287                  6.85 ± 0.11                   0.00 ± 0.00                         6.85
  LYC1303                  6.83 ± 0.02                   0.00 ± 0.00                         6.83
  LYC1322                  7.07 ± 0.01                   5.72 ± 0.03                         1.35

###### 

Bile salt tolerance test results for 57 *Lactobacillus* isolates at pH 7.3 with 0.3% Oxgall.

  *Lactobacillus* strain   Cell viability (log CFU/ml)   Reduction in cell viability (log)   
  ------------------------ ----------------------------- ----------------------------------- ------
  LUC0018                  9.67 ± 0.10                   8.62 ± 0.11                         1.05
  LUC0040                  9.78 ± 0.18                   8.60 ± 0.08                         1.18
  LUC0044                  9.99 ± 0.02                   8.48 ± 0.00                         1.51
  LUC0048                  9.93 ± 0.07                   8.79 ± 0.07                         1.14
  LUC0095                  8.99 ± 0.08                   8.08 ± 0.00                         0.91
  LUC0097                  9.88 ± 0.10                   8.67 ± 0.10                         1.21
  LUC0103                  9.03 ± 0.14                   8.41 ± 0.40                         0.62
  LUC0113                  9.80 ± 0.02                   8.97 ± 0.10                         0.83
  LUC0114                  9.65 ± 0.00                   9.06 ± 0.05                         0.59
  LUC0115                  9.81 ± 0.00                   9.00 ± 0.11                         0.81
  LUC0123                  9.07 ± 0.20                   8.41 ± 0.34                         0.66
  LUC0125                  9.85 ± 0.00                   8.38 ± 0.38                         1.47
  LUC0127                  9.25 ± 0.07                   8.44 ± 0.06                         0.81
  LUC0128                  9.65 ± 0.00                   8.65 ± 0.00                         1.00
  LUC0168                  9.20 ± 0.14                   8.83 ± 0.13                         0.37
  LUC0174                  9.40 ± 0.00                   9.14 ± 0.06                         0.26
  LUC0180                  9.30 ± 0.00                   8.70 ± 0.06                         0.60
  LUC0182                  9.81 ± 0.16                   9.13 ± 0.09                         0.68
  LUC0191                  9.34 ± 0.45                   8.88 ± 0.10                         0.46
  LUC0192                  10.02 ± 0.00                  8.85 ± 0.11                         1.17
  LUC0197                  9.19 ± 0.16                   8.30 ± 0.14                         0.89
  LUC0219                  9.33 ± 0.20                   8.99 ± 0.12                         0.34
  LYC0289                  9.16 ± 0.02                   8.11 ± 0.05                         1.05
  LYC0413                  9.02 ± 0.00                   8.59 ± 0.27                         0.43
  LYC1031                  9.98 ± 0.00                   8.88 ± 0.10                         1.10
  LYC1037                  9.81 ± 0.00                   9.11 ± 0.05                         0.70
  LYC1038                  8.74 ± 0.06                   6.99 ± 0.05                         1.75
  LYC1039                  9.10 ± 0.06                   8.55 ± 0.21                         0.55
  LYC1065                  9.18 ± 0.00                   8.87 ± 0.04                         0.30
  LYC1088                  9.74 ± 0.00                   9.09 ± 0.06                         0.65
  LYC1112                  9.40 ± 0.00                   8.88 ± 0.10                         0.52
  LYC1113                  9.88 ± 0.00                   9.36 ± 0.41                         0.52
  LYC1115                  9.13 ± 0.01                   8.13 ± 0.02                         1.00
  LYC1117                  9.30 ± 0.25                   8.41 ± 0.41                         0.89
  LYC1118                  9.15 ± 0.21                   8.94 ± 0.18                         0.21
  LYC1119                  9.10 ± 0.17                   8.44 ± 0.37                         0.66
  LYC1120                  9.81 ± 0.00                   8.88 ± 0.10                         0.93
  LYC1138                  9.14 ± 0.06                   8.37 ± 0.32                         0.77
  LYC1141                  9.02 ± 0.20                   8.68 ± 0.03                         0.34
  LYC1142                  9.06 ± 0.12                   8.26 ± 0.31                         0.80
  LYC1143                  9.26 ± 0.19                   8.76 ± 0.03                         0.50
  LYC1144                  9.78 ± 0.00                   9.06 ± 0.08                         0.72
  LYC1146                  9.54 ± 0.00                   8.47 ± 0.10                         1.07
  LYC1149                  9.13 ± 0.00                   8.08 ± 0.08                         1.05
  LYC1151                  9.08 ± 0.09                   8.65 ± 0.07                         0.43
  LYC1152                  9.48 ± 0.00                   9.02 ± 0.03                         0.46
  LYC1154                  9.39 ± 0.30                   8.78 ± 0.00                         0.61
  LYC1156                  9.24 ± 0.23                   8.36 ± 0.26                         0.88
  LYC1159                  9.85 ± 0.00                   8.04 ± 0.03                         1.81
  LYC1162                  9.65 ± 0.00                   8.48 ± 0.25                         1.17
  LYC1164                  9.12 ± 0.06                   7.02 ± 0.06                         2.10
  LYC1229                  9.42 ± 0.17                   8.45 ± 0.21                         0.97
  LYC1235                  9.22 ± 0.24                   8.71 ± 0.15                         0.51
  LYC1237                  9.10 ± 0.02                   8.94 ± 0.05                         0.16
  LYC1287                  9.23 ± 0.05                   8.05 ± 0.11                         1.18
  LYC1303                  9.78 ± 0.00                   8.74 ± 0.00                         1.04
  LYC1322                  9.54 ± 0.00                   8.12 ± 0.03                         1.42

The Results of the Agar Well Diffusion Method
---------------------------------------------

The 21 isolates displayed the greatest activity against carbapenem-resistant *E. coli* with zones of inhibition greater than 15 mm ([Figure 2A](#F2){ref-type="fig"}). The greatest activity against carbapenem-resistant *K. pneumoniae* isolates, with zones of inhibition greater than or equal to 15 mm, were observed in the nine isolates ([Figure 2B](#F2){ref-type="fig"}). Overall, we chose five *Lactobacillus* strains (LUC0180, LUC0219, LYC0289, LYC0413, and LYC1031), which had the significantly better antibacterial activities than the most of the other strains (*p* \< 0.05) as determined by the agar well diffusion and time-kill assay for further tests of antibacterial activity.

![**(A)** Zone of inhibition of 31 *Lactobacillus* isolates against carbapenem-resistant *E. coli* by well diffusion assays. (a, b, c, d, e five isolates showed the significantly better activity than all of the other strains (all *p* \< 0.05). However, there was no significant differences among them). **(B)** Zone of inhibition of 31 *Lactobacillus* isolates against carbapenem-resistant *K. pneumoniae* by well diffusion assays. \[a, b, c, d, e five isolates showed the significantly better activity than all of the other strains (all *p* \< 0.05). However, there was no significant differences among them\].](fmicb-10-00789-g002){#F2}

The Results of MIP/MBP Tests
----------------------------

[Table 5](#T5){ref-type="table"} shows the MIP and MBP for the five most potent *Lactobacillus* supernatants against CRE. The MIP of these five strains ranged from 10 to 30%. Except for LUC0180, which had an MBP of ≥40%, all of the strains had MBPs ranging from 20 -- 40%. The inhibitory effects of these *Lactobacillus* strains did not change after heating up to 80°C for 10 min. However, the inhibitory effect disappeared once the pH increased to 7.0 (data not show). Additionally, the pH in the presence of LUC0180 seemed to be higher than the other four isolates.

###### 

The resulting pH and MIPs/MBPs of five *Lactobacillus* strain supernatants (%) against carbapenem-resistant *E. coli* (CREC) and *K. pneumoniae* (CRKP).

  CREC       pH       CRE78        CRE108       CRE128       CRE178       CRE202       CRE236       CRE240       CRE361       CRE387       CRE397
  ---------- -------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  LUC0180    4.01     20/40        20/40        20/40        20/40        20/40        20/30        20/40        20/40        30/\>50      30/\>50
  LUC0219    3.86     10/30        10/40        10/40        10/40        10/30        10/30        10/40        10/40        20/40        20/40
  LYC0289    3.76     10/30        10/40        10/30        10/40        10/30        10/30        10/30        10/30        10/30        10/40
  LYC0413    3.82     10/20        10/30        10/20        10/30        10/20        10/20        10/30        10/30        10/30        10/30
  LYC1031    3.84     10/30        10/40        10/30        10/40        10/30        10/30        10/30        10/30        10/30        10/30
                                                                                                                                           
  **CRKP**   **pH**   **CRE632**   **CRE716**   **CRE804**   **CRE825**   **CRE831**   **CRE851**   **CRE919**   **CRE929**   **CRE944**   **CRE945**
                                                                                                                                           
  LUC0180    4.01     20/40        20/40        20/30        20/30        20/30        20/30        20/30        20/40        20/30        20/30
  LUC0219    3.86     10/40        10/30        10/30        10/30        10/30        10/30        10/20        10/30        10/20        10/30
  LYC0289    3.76     10/30        10/30        10/30        10/20        10/20        10/30        10/20        10/30        10/20        10/20
  LYC0413    3.82     10/20        20/20        10/20        20/20        10/20        20/20        10/20        20/20        10/20        20/30
  LYC1031    3.84     10/40        10/30        10/30        10/20        10/30        10/30        10/20        10/30        10/20        10/20

The Results of Time-Kill Test
-----------------------------

[Figure 3](#F3){ref-type="fig"} shows the results from time-killing test and assessment of the association between pH and antibacterial effects. After a 24-h incubation, there was no significant change between mono-cultures of lactobacilli and co-culture of lactobacilli and carbapenem-resistant *E. coli* (CRE316) in term of the concentration of lactobacilli (all *p* \> 0.05) ([Figure 3A](#F3){ref-type="fig"}). In contrast, the growth of CRE 316 was significantly inhibited after co-culture with different concentration lactobacilli after 24 h (all *p* \< 0.05) and even 48 h (*p* \< 0.0001) when comparing with mono-culture of CRE ([Figure 3B](#F3){ref-type="fig"}). Furthermore, the decreases in pH were observed in the mono-cultures of lactobacilli,especially at the concentration of 10^8^ and 10^7^ CFU/ml (both *p* \< 0.05) ([Figure 3C](#F3){ref-type="fig"}). The decrease in pH remains significant while in the co-cultures with CRE316 compared with CRE316 monoculture (all *p* \< 0.05, [Figure 3D](#F3){ref-type="fig"}). The similar findings were also noted for the co-culture with carbapenem-resistant *K. pneumonia* (CR632) ([Figure 3E--H](#F3){ref-type="fig"}).

![**(A,E)** The CFU change of five different concentration (10^5^ to 10^8^ CFU/ml) *Lactobacillus* isolates after mono-culture or co-culture with CRE316/ 632 for 48 h. **(B,F)** The CFU change of CRE316/ 632 after mono-culture or co-culture with five different concentration (10^5^ to 10^8^ CFU/ml) *Lactobacillus* isolates for 48 h and comparison between mono-culture and co-culture. **(C,G)** The pH changes of five different concentration (10^5^ to 10^8^ CFU/ml) *Lactobacillus* isolates mono-culture for 48 h. **(D,H)** The pH changes of CRE316/ 632 after mono-culture or co-culture with five different concentration (10^5^ to 10^8^ CFU/ml) *Lactobacillus* isolates and comparison between mono-culture and co-culture. (^a^ Means the comparisons between 10^8^ and 10^5,6,7^ CFU/ml lactobacillus isolates. ^b^ Means the comparisons between 10^7^ and 10^5,6^ CFU/ml *Lactobacillus* isolates. ∗*P*-value \< 0.05, \#*P*-value \< 0.001, &*P*-value \< 0.0001).](fmicb-10-00789-g003){#F3}

Discussion
==========

In this study, five *Lactobacillus* strains, including three *L. plantarum* strains (LUC0219, LYC0289, LYC1031) and one each of *L. paracaseri* (LUC0180) and *L. rhamnosus* (LYC0413), exhibited good antibacterial activity against CREs. These inhibitory effects were demonstrated in through various tests including the agar well diffusion method, broth microdilution assay, and time-kill test. *Lactobacillus* spp. are non-pathogenic Gram-positive rods that are also recognized as normal human flora. Recently, several studies have reported that *Lactobacillus* strains can exhibit antibacterial activity through several mechanisms such as the production of antimicrobial substances or metabolites (hydrogen peroxide, lactic acid, bacteriocin), competition for nutrients, inhibition of bacterial adhesion to the mucosa, and enhancement of the immune response ([@B10]; [@B23]; [@B26]; [@B25]). Some *in vitro* studies have also shown that *Lactobacillus* strains can exhibit antimicrobial activity against *C. difficile*, *E. coli*, *Shigella* spp., *S. mutans, P. aeruginosa*, and *S. aureus* ([@B14]; [@B22]; [@B18]; [@B16]; [@B1]). To the best of our knowledge, this is the first study to document evidence of *Lactobacillus* antimicrobial activity against CRE. Although *in vitro* activity cannot be directly translated to *in vivo* effect, our findings suggest a promising role for *Lactobacillus* strains in the prevention and treatment of CRE colonization or infection. However, further animal studies are warranted to clarify this issue.

In the time-kill studies, the co-cultures with CREs did not influence the growth of lactobacilli. Additionally, effective inhibitory activity was generally observed at a pH of less than 4.2. These results were comparable with what we observed in our MIP/MBP experiments. By contrast, the antibacterial activity of *Lactobacillus* strains was dependent on an acidic environment and the inhibitory effect disappeared once the pH became greater than 6.5 during the MIP/MBP tests. Importantly, antimicrobial activity was not influenced by heating. This indicates that the inhibitory effect is mostly due to the acidic conditions, and not the production of bacteriocin-like substances. Similar findings were noted in the time-kill test. Previous reports have shown that the production of organic acids by probiotic organisms and the resulting decrease in culture pH is considered to be the principal antimicrobial effect ([@B35]; [@B31]). In addition to lowering the culture pH, [@B2] reported that organic acids could also function as outer membrane permeabilizers of some gram-negative bacteria and enhance the activity of other antimicrobial metabolites. These findings suggest that acidic pH and/or the presence of organic acids may be essential for the antibacterial activity observed in the present study.

In this study, only 31 of the 57 *Lactobacillus* strains that were initially collected for assessment were found to be able to survive in the simulated gastric and intestinal environment. For clinical application, these characteristics are extremely important. To be functional in the lower enteric tract, the tolerance of lactobacilli to pepsin, low pH and bile salts is essential.

This study had several limitations. First, in addition to the effect of acid environment, we did not investigate the detail mechanism or molecular effectors of these function traits. Second, we used separated tests instead of a unique trait by using *in vitro* GIT system to evaluate the GIT resistance in this study. Further study is warranted to clarify these issues.

Conclusion
==========

Several *Lactobacillus* strains exhibit antibacterial activity against CRE. We suggest that this effect may have potential applications through the use of *Lactobacillus* strains as starter cultures in fermented foods or as food preservatives for controlling or preventing CRE infections. Additional studies are required to determine the effects of complex nutrients on the synthesis of the antibacterial substance, as well as to elucidate the mechanisms and genetic basis of the bactericidal activity. Further animal models are also necessary to document the *in vivo* survival of these acid, pepsin and bile salt tolerant lactobacilli in the lower enteric tract. If the same inhibitory effect can be documented *in vivo*, further studies including vancomycin-resistant *Enterococcus* should be performed in the future.
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